TORONTO, June 19, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces voting results from its Annual Meeting of Shareholders held on June 19, 2020 in Toronto, Ontario.
A total of 29,525,760 Common Shares, or 93.02% of the total Common Shares issued and outstanding, were voted by proxy at the meeting. Each director nominee was elected by a show of hands. Based on proxies received prior to the meeting, voting by individual director was as follows:
J. Spencer Lanthier
Shareholders also voted in favour of the re-appointment of Ernst & Young LLP as HLS's auditors.
ABOUT HLS THERAPEUTICS INC.
Formed in 2015, HLS is a specialty pharmaceutical company focused on the acquisition and commercialization of late stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information, please visit: www.hlstherapeutics.com
SOURCE HLS Therapeutics Inc.